304 (PB084) - Pharmacological screening identified promising combination partners in marginal zone lymphoma models with secondary resistance to BTK and PI3K inhibitors.
Saved in:
| Title: | 304 (PB084) - Pharmacological screening identified promising combination partners in marginal zone lymphoma models with secondary resistance to BTK and PI3K inhibitors. |
|---|---|
| Authors: | Arribas, A.1 (AUTHOR), Vultaggio, S.2 (AUTHOR), Andronache, A.2 (AUTHOR), Robusto, M.2 (AUTHOR), Fancelli, D.2 (AUTHOR), Cannas, E.1 (AUTHOR), Spriano, F.1 (AUTHOR), Tarantelli, C.1 (AUTHOR), Rossi, D.3 (AUTHOR), Zucca, E.3 (AUTHOR), Stathis, A.3 (AUTHOR), Varasi, M.2 (AUTHOR), Mercurio, C.2 (AUTHOR), Bertoni, F.1 (AUTHOR) |
| Source: | European Journal of Cancer. 2022 Supplement 1, Vol. 174, pS108-S108. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
